Beyond the Cure: The Children’s Oncology Group Uses Evidence and Clinical Trials to Study Late Effects in Childhood Cancer Survivors (C229)

11:30 am–12:30 pm Saturday, September 7

coglogoChildhood cancer survivors are living longer than ever before, with overall survival rates exceeding 80%. As a result, survivors are living with chronic late health effects related to their curative treatments. Late effects may include second malignancies, endocrinopathies, cardiomyopathy, infertility, pulmonary function deficits, renal/ocular/auditory disorders, neurocognitive deficits, and metabolic syndrome.

The estimated prevalence of developing a late effect is 95% by age 45, with 80% of those being serious/disabling or life-threatening. Twenty percent of survivors will also develop a treatment-related second malignancy within 30 years. This evidence supports a survivor’s need for specific education regarding their unique risk for late effects. Early detection through screening and prompt intervention/treatment is vital in order to minimize the burden of late effects that can negatively impact the survivor’s quality of life. Substantial data regarding the late effects of traditional chemotherapy and radiotherapy are now available. This session will use survivor-specific exemplars to examine treatment-related exposures and potential subsequent late effects. Open Children’s Oncology Group (COG) studies will be highlighted through the patient exemplars. The newly updated Children’s COG Long-Term Follow-Up Guidelines will direct these surveillance recommendations.

Eleanor Hendershot, MN BScN RN(EC)
CNE Hours:
RX Hours: